Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats (Q30879183)

27 June 2017

Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats (English)

1 reference

27 June 2017

0 references

2

Hans-Willi Krell

0 references

Klaus Jung

object named as

Klaus Jung

1

1 reference

ORCID Public Data File 2021

author name string

Hans-Willi Krell

2

1 reference

27 June 2017

Bernhard Ortel

3

1 reference

27 June 2017

Tayyaba Hasan

4

1 reference

27 June 2017

Andreas Römer

5

1 reference

27 June 2017

Dietmar Schnorr

6

1 reference

27 June 2017

Stefan A Loening

7

1 reference

27 June 2017

Michael Lein

8

1 reference

27 June 2017

1 February 2003

1 reference

27 June 2017

1 reference

27 June 2017

54

1 reference

27 June 2017

3

1 reference

27 June 2017

206-211

1 reference

Matrix metalloproteinases: biologic activity and clinical implications

27 June 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Proteases in invasion: matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Preclinical and clinical studies of MMP inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Workgroup I: rodent models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

Quantification of matrix metalloproteinases in tissue samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10183

21 January 2018

Identifiers

DOI

10.1002/PROS.10183

1 reference

27 June 2017

1 reference